Complement activation by oxidatively modified low-density lipoproteins

European Journal of Clinical Investigation

Volumn 29, Issue 10, 1999, Pages 835-841

  Wieland, E ^a,c   Dorweiler, B ^b   Bonitz, U ^a   Lieser, S ^b   Walev, I ^a,b   Bhakdi, S ^b  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

^b JOHANNES GUTENBERG UNIVERSITY   (Germany)

^c UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

Author keywords

Atherosclerosis; Complement; Inflammation; Lesion complement activator; Oxidized low density lipoprotein

Indexed keywords

COMPLEMENT COMPONENT C3; COMPLEMENT MEMBRANE ATTACK COMPLEX; LOW DENSITY LIPOPROTEIN;

ARTICLE; ATHEROSCLEROSIS; COMPLEMENT ACTIVATION; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; LIPID PEROXIDATION; PRIORITY JOURNAL;

ARTERIOSCLEROSIS; CHOLESTEROL; COMPLEMENT ACTIVATION; COMPLEMENT C3; HUMANS; LIPID PEROXIDATION; LIPOPROTEINS, LDL; MALONDIALDEHYDE; OXIDATION-REDUCTION;

EID: 0032858529     PISSN: 00142972     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2362.1999.00548.x     Document Type: Article

References (27)

1. 1 Brown MS, Goldstein JL. Lipoprotein metabolism in the macrophage: implications for cholesterol deposition in atherosclerosis. Annu Rev Biochem, 1983;52:223-61.
2. 2 Goldstein JL, Ho YK, Basu SK, Brown MS. Binding site on macrophages that mediates uptake and degradation of acetylated low density lipoprotein, producing massive cholesterol deposition. Proc Natl Acad Sci USA, 1979;76:333-7.
3. 3 Steinberg D, Parthasarathy S, Carew T, Khoo J, Witztum JL. Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenecity. N Engl J Med 1989;320:915-24.
4. 4 Steinbrecher UP, Parthasarathy S, Leake DS, Witztum JL, Steinberg D. Modification of low density lipoprotein by endothelial cells involves lipid peroxidation and degradation of low density lipoprotein phospholipids. Proc Natl Acad Sci USA, 1984;81:3883-7.
5. 5 Wieland E, Parthasarathy S, Steinberg D. Peroxidase-dependent metal-independent oxidation of low density lipoprotein in vitro: a model for in vivo oxidation? Proc Natl Acad Sci USA, 1993;90:5929-33.
6. 6 Steinbrecher UP. Oxidation of human low density lipoprotein results in derivatization of lysine residues of apolipoprotein B by lipid peroxide decomposition products. J Biol Chem, 1987;262:3603-8.
7. 7 Rajavashisth TB, Andalibi A, Territo MC, Berliner JA, Navab M, Fogelman AM, et al. Induction of endothelial cell expression of granulocyte and macrophage colony-stimulating factors by modified low-density lipoproteins. Nature, 1990;344:254-7.
8. 8 Esterbauer H, Gebicki J, Puhl H, Jürgens G. The role of lipid peroxidation and antioxidants in oxidative modification of LDL. Free Rad Biol Med, 1992;13:341-90.
9. 9 Torzewski M, Klouche M, Hock J, Messner M, Dorweiler B, Torzewski J, et al. Immunohistochemical demonstration of enzymatically modified human LDL and its colocalization with the terminal complement complex in early atherosclerotic lesion. Arterioscler Thromb Vasc Biol, 1998;18:369-78.
10. 10 Seifert PS, Hugo F, Hansson GK, Bhakdi S. Prelesional complement activation in experimental atherosclerosis. Terminal C5b-9 complement deposition coincides with cholesterol accumulation in the aortic intima of hypercholesterolemic rabbits. Lab Invest, 1989;60:747-54.
11. 11 Seifert PS, Hugo F, Tranum-Jensen J, Zähringer U, Muhly M, Bhakdi S. Isolation and characterization of a complement activating lipid extracted from human atherosclerotic lesions. J Exp Med, 1990;172:547-57.
12. 12 Havel RJ, Eder HA, Bragdon JH. The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. J Clin Invest, 1955;34:1345-53.
13. 13 Wieland E, Schettler V, Diedrich F, Schuff-Werner P, Oellerich M. Determination of lipid hydroperoxides in serum: iodometry HPLC compared. Eur J Clin Chem Clin Biochem, 1992;30:363-9.
14. 14 Parthasarathy S, Wieland E, Steinberg D. A role for endothelial cell lipoxygenase in the oxidative modification of low density lipoprotein. Proc Natl Acad Sci USA, 1989;86:1046-50.
15. 15 Hugo F, Krämer S, Bhakdi S. Sensitive ELISA for quantitating the terminal membrane C5b-9 and fluid phase SC5b-9 complex of human complement. J Immunol Methods, 1987;99:243-51.
16. 16 Bhakdi S, Roth M, Nürnberger W. A simple method for quantitative measurement of C3d in human plasma. J Immunol Methods, 1984;74:79-86.
17. 17 Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the folin phenol reagent. J Biol Chem, 1951;193:265-75.
18. 18 Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature, 1993;362:801-9.
19. 19 Quinn MT, Parthasarathy S, Fong LG, Steinberg D. Oxidatively modified low density lipoproteins: a potential role in recruitment and retention of monocytes/macrophages during atherogenesis. Proc Natl Acad Sci USA, 1987;84:2995-8.
20. 20 Thomas CE, Jackson RL, Ohlweiler DF, Ku G. Multiple lipid oxidation products in low density lipoproteins induce interleukin-1 beta release from human blood mononuclear cells. J Lipid Res, 1994;35:417-27.
21. 21 Liao F, Berliner JA, Mehrabian M, Navab M, Demer LL, Lusis AJ, et al. Minimally modified low density lipoprotein is biologically active in vivo in mice. J Clin Invest, 1991;87:2253-7.
22. 22 Bhakdi S, Dorweiler B, Kirchmann R, Torzeewski J, Weise E, Tranum-Jensen J, et al. On the pathogenesis of atherosclerosis: enzymatic transformation of human low density lipoprotein to an atherogenic moiety. J Exp Med, 1995;182:1959-71.
23. 23 Klouche M, Gottschling S, Gerl V, Hell W, Husmann M, Dorweiler B, et al. Atherogenic properties of enzymatically degraded LDL. selective induction of MCP-1 and cytotoxic effects on human macrophages. Arterioscler Thromb Vasc Biol, 1998;18:1376-85.
24. 24 Bhakdi S. Complement and atherogenesis: the unknown connection. Ann Med, 1998;30:503-7.
25. 25 Vlaicu R, Niculescu F, Rus HG, Cristea A. Immunohistochemical localization of the terminal C5b-9 complement complex in human aortic fibrous plaque. Atherosclerosis, 1985;75:163-77.
26. 26 Ylä-Herttuala S, Rosenfeld ME, Parthasarathy S, Sigal E, Särkija T, Witztum JL, et al. Gene expression in macrophagerich human atherosclerotic lesions. 15-lipoxygenase and acetyl low density lipoprotein receptor messenger RNA colocalize with oxidation specific lipid-protein adducts. J Clin Invest, 1991;87:1146-52.
27. 27 Alving CR, Richards RL, Guirguis AA. Cholesterol-dependent human complement activation resulting in damage to liposomal model membranes. J Immunol, 1977;118:342-7.